In one paragraphArticle in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Iris M De CuyperSanquin Blood Supply Foundation, Department Research, 1066 CX Amsterdam, The Netherlands.ORCID 0000-0001-8862-8000 Graciela Carbajo-ArgüellesPlatelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0001-6547-7609 María Villa-FajardoDepartment of Hematology, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, 28040 Madrid, Spain.
Andrea Acebes-HuertaPlatelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-7106-3063 Rutger A MiddelburgCenter for Clinical Transfusion Research, Sanquin Blood Supply Foundation, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-6545-7277 Johannes A EbleInstitute of Physiological Chemistry and Pathobiochemistry, University of Münster, 48149 Münster, Germany.ORCID 0000-0001-9156-2137 Dick H W DekkersCenter for Proteomics, Erasmus University Medical Center (Erasmus MC), 3015 CN Rotterdam, The Netherlands.ORCID 0000-0001-7057-6257 Jeroen A A DemmersCenter for Proteomics, Erasmus University Medical Center (Erasmus MC), 3015 CN Rotterdam, The Netherlands.
Jean-Louis H KerkhoffsCenter for Clinical Transfusion Research, Sanquin Blood Supply Foundation, 2333 ZA Leiden, The Netherlands.
Jaap Jan ZwagingaCenter for Clinical Transfusion Research, Sanquin Blood Supply Foundation, 2333 ZA Leiden, The Netherlands.ORCID 0000-0003-1228-7769 Laura GutiérrezPlatelet Research Lab, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0001-8443-900X Funding
Deutsche Forschungsgemeinschaft EB177/19-1Instituto de Investigación Sanitaria del Principado de Asturias Postdoctoral Grant 2018Instituto de salud Carlos III CB/07/09/0020Ministerio de Ciencia, Innovación y Universidades DIN2024Ministerio de Ciencia, Innovación y Universidades PID2020-117265GB-I00Ministerio de Ciencia, Innovación y Universidades SAF2017-85489-PMinisterio de Economía y Competitividad RYC-2013-12587
6 · The paper itselfAbstract
Hemato-oncological patients with chemotherapy-induced thrombocytopenia are a major recipient group of frequent platelet (PLT) transfusion. Prophylactic platelet transfusions are administered when platelet counts fall below 10 × 10
Indexed as
Blood PlateletsGlycoproteinsLeukemia, Myeloid, AcuteThrombocytopeniaAdultFemaleHumansMaleMiddle AgedPlatelet TransfusionProteomicsGlycoproteinschemotherapyhemato-oncological patientsplasma factorsplatelet functionplatelet transfusionvWF
Identifiers
PMID42352230
PMCPMC13296933
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390